Please assess the completion status of the following clinical trial:

Trial Title: Study of Netarsudil Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Must be 18 years of age or older~2. Diagnosis of open primary angle glaucoma(POAG) or ocular hypertension (OHT) in both eyes~3. Unmedicated intraocular pressure (IOP) \>20 mmHg and \< 30 mmHg in both eyes at first qualification visit~4. Best corrected visual acuity (BCVA) equivalent to 20/200 Snellen or better~5. Able to give informed consent and follow study instructions~Exclusion Criteria:~Ophthalmic:~1. Clinically significant ocular disease~2. Pseudoexfoliation or pigment dispersion component glaucoma, history of angle closure glaucoma, or narrow angles~3. Intraocular pressure ≥30 mmHg in either eye~4. A difference in IOP between eyes \>4mmHg at qualification visit~5. Use of more than two ocular hypotensive medications within 30 days of screening~6. Known hypersensitivity to any component of the formulation~7. Previous glaucoma surgery or refractive surgery~8. Keratorefractive surgery in either eye~9. Report of ocular injury in either eye within the six months prior to screening or ocular or non-refractive surgery within 3 months prior to screening~10. Recent or current ocular infection or inflammation in either eye~11. Use of ocular medication in either eye of any kind within 30 days of screening~12. Mean central corneal thickness greater than 620 μm in either eye~13. Any abnormality preventing reliable applanation tonometry of either eye~14. Lack of suitable episcleral vein prior to performing Episcleral Venus Pressure (EVP) measurement (applicable to 1 site only)~    Systemic:~15. Clinically significant abnormalities within 6 weeks prior to screening~16. Clinically significant systemic disease~17. Participation in any investigational study within 60 days prior to screening~18. Use of systemic medication that could have an effect on intraocular pressure within 30 days prior to screening~19. Women of childbearing potential who were pregnant, nursing, planning a pregnancy, or not using a medically acceptable form of birth control

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Netarsudil Ophthalmic Solution 0.02% (Type: EXPERIMENTAL): Netarsudil Ophthalmic Solution 0.02% was administered in one eye and Placebo comparator in contralateral eye
- Placebo Comparator (Type: PLACEBO_COMPARATOR): Placebo comparator administered in one eye and Netarsudil Ophthalmic Solution 0.02% in contralateral eye

Based on this trial design, predict the completion outcome and termination type (if applicable).